{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T00:10:11Z","timestamp":1748477411210,"version":"3.41.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,28]]},"DOI":"10.7759\/cureus.84998","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T23:53:03Z","timestamp":1748476383000},"source":"Crossref","is-referenced-by-count":0,"title":["The Role of Metabolic Parameters of 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18F-FDG PET-CT) Imaging in Predicting Progression-Free Survival of Radioiodine-Refractory Differentiated Thyroid Cancer: A Single-Center Stud"],"prefix":"10.7759","author":[{"given":"Alireza","family":"Khatami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duncan","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Romsa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164102","article-title":"Long-term survival analysis and prognostic factors of Arabic patients with differentiated thyroid carcinoma: A 20-year observational study at the King Hussein Cancer Center (khcc) involving 528 patients","volume":"15","author":"Al-Ibraheem A","year":"2023","unstructured":"Al-Ibraheem A, Al-Rasheed U, Mashhadani N, et al.. Long-term survival analysis and prognostic factors of Arabic patients with differentiated thyroid carcinoma: A 20-year observational study at the King Hussein Cancer Center (khcc) involving 528 patients. Cancers (Basel). 2023, 15:4102. 10.3390\/cancers15164102","journal-title":"Cancers (Basel)"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.269091","article-title":"Impact of radioactive iodine treatment on long-term relative survival in patients with papillary and follicular thyroid cancer: A SEER-based study covering histologic subtypes and recurrence risk categories","volume":"66","author":"Weis H","year":"2025","unstructured":"Weis H, Weindler J, Schmidt K, Hellmich M, Drzezga A, Schmidt M. Impact of radioactive iodine treatment on long-term relative survival in patients with papillary and follicular thyroid cancer: A SEER-based study covering histologic subtypes and recurrence risk categories. J Nucl Med. 2025, 66:525-30. 10.2967\/jnumed.124.269091","journal-title":"J Nucl Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60109-9","article-title":"Progress in molecular-based management of differentiated thyroid cancer","volume":"381","author":"Xing M","year":"2013","unstructured":"Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013, 381:1058-69. 10.1016\/S0140-6736(13)60109-9","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.5306\/wjco.v13.i1.9","article-title":"New approaches for patients with advanced radioiodine-refractory thyroid cancer","volume":"13","author":"Pitoia F","year":"2022","unstructured":"Pitoia F, Jerkovich F, Trimboli P, Smulever A. New approaches for patients with advanced radioiodine-refractory thyroid cancer. World J Clin Oncol. 2022, 13:9-27. 10.5306\/wjco.v13.i1.9","journal-title":"World J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1590\/2359-3997000000245","article-title":"Radioactive iodine-refractory differentiated thyroid cancer: An uncommon but challenging situation","volume":"61","author":"Schmidt A","year":"2017","unstructured":"Schmidt A, Iglesias L, Klain M, Pitoia F, Schlumberger MJ. Radioactive iodine-refractory differentiated thyroid cancer: An uncommon but challenging situation. Arch Endocrinol Metab. 2017, 61:81-9. 10.1590\/2359-3997000000245","journal-title":"Arch Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0104","article-title":"Survival from differentiated thyroid cancer: What has age got to do with it?","volume":"25","author":"Ganly I","year":"2015","unstructured":"Ganly I, Nixon IJ, Wang LY, et al.. Survival from differentiated thyroid cancer: What has age got to do with it?. Thyroid. 2015, 25:1106-14. 10.1089\/thy.2015.0104","journal-title":"Thyroid"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12020506","article-title":"2-[(18)F]FDG PET in the management of radioiodine refractory differentiated thyroid cancer in the era of thyrosin-kinases inhibitors: A real-life retrospective study","volume":"12","author":"Gay S","year":"2022","unstructured":"Gay S, Raffa S, De'Luca di Pietralata A, et al.. 2-[(18)F]FDG PET in the management of radioiodine refractory differentiated thyroid cancer in the era of thyrosin-kinases inhibitors: A real-life retrospective study. Diagnostics. 2022, 12:506. 10.3390\/diagnostics12020506","journal-title":"Diagnostics"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial","volume":"384","author":"Brose MS","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, et al.. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet. 2014, 384:319-28. 10.1016\/S0140-6736(14)60421-9","journal-title":"Lancet"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.6472","article-title":"Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial","volume":"35","author":"Brose MS","year":"2017","unstructured":"Brose MS, Worden FP, Newbold KL, Guo M, Hurria A. Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. J Clin Oncol. 2017, 35:2692-9. 10.1200\/JCO.2016.71.6472","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen BR","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, et al.. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016, 26:1-133. 10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-17-0542","article-title":"Treatment of refractory thyroid cancer","volume":"25","author":"Berdelou A","year":"2018","unstructured":"Berdelou A, Lamartina L, Klain M, Leboulleux S, Schlumberger M. Treatment of refractory thyroid cancer. Endocr Relat Cancer. 2018, 25:R209-23. 10.1530\/ERC-17-0542","journal-title":"Endocr Relat Cancer"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2011.0322","article-title":"Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment","volume":"22","author":"Han JM","year":"2012","unstructured":"Han JM, Kim WB, Yim JH, et al.. Long-term clinical outcome of differentiated thyroid cancer patients with undetectable stimulated thyroglobulin level one year after initial treatment. Thyroid. 2012, 22:784-90. 10.1089\/thy.2011.0322","journal-title":"Thyroid"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-2695","article-title":"Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin","volume":"96","author":"Malandrino P","year":"2011","unstructured":"Malandrino P, Latina A, Marescalco S, et al.. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab. 2011, 96:1703-9. 10.1210\/jc.2010-2695","journal-title":"J Clin Endocrinol Metab"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0648","article-title":"The role of thyroglobulin doubling time in differentiated thyroid cancer: A meta-analysis","volume":"11","author":"Giovanella L","year":"2022","unstructured":"Giovanella L, Garo ML, Albano D, G\u00f6rges R, Ceriani L. The role of thyroglobulin doubling time in differentiated thyroid cancer: A meta-analysis. Endocr Connect. 2022, 11:e210648. 10.1530\/EC-21-0648","journal-title":"Endocr Connect"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-021-02755-5","article-title":"The role of Tg kinetics in predicting 2-[(18)F]-FDG PET\/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan","volume":"74","author":"Albano D","year":"2021","unstructured":"Albano D, Tulchinsky M, Dondi F, Mazzoletti A, Bertagna F, Giubbini R. The role of Tg kinetics in predicting 2-[(18)F]-FDG PET\/CT results and overall survival in patients affected by differentiated thyroid carcinoma with detectable Tg and negative 131I-scan. Endocrine. 2021, 74:332-9. 10.1007\/s12020-021-02755-5","journal-title":"Endocrine"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/srep28081","article-title":"Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience","volume":"6","author":"Werner RA","year":"2016","unstructured":"Werner RA, L\u00fcckerath K, Schmid JS, et al.. Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment - initial experience. Sci Rep. 2016, 6:28081. 10.1038\/srep28081","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.diii.2021.04.004","article-title":"PET\/CT in the management of differentiated thyroid cancer","volume":"102","author":"Zampella E","year":"2021","unstructured":"Zampella E, Klain M, Pace L, Cuocolo A. PET\/CT in the management of differentiated thyroid cancer. Diagn Interv Imaging. 2021, 102:515-23. 10.1016\/j.diii.2021.04.004","journal-title":"Diagn Interv Imaging"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-1534","article-title":"Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning","volume":"91","author":"Robbins RJ","year":"2006","unstructured":"Robbins RJ, Wan Q, Grewal RK, et al.. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006, 91:498-505. 10.1210\/jc.2005-1534","journal-title":"J Clin Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109612","article-title":"The usefulness of standardized uptake value in differentiation between benign and malignant thyroid lesions detected incidentally in 18F-FDG PET\/CT examination","volume":"9","author":"Stangierski A","year":"2014","unstructured":"Stangierski A, Woli\u0144ski K, Czepczy\u0144ski R, et al.. The usefulness of standardized uptake value in differentiation between benign and malignant thyroid lesions detected incidentally in 18F-FDG PET\/CT examination. PLoS One. 2014, 9:e109612. 10.1371\/journal.pone.0109612","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.111.099531","article-title":"18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: Adding value to clinical staging","volume":"53","author":"Dibble EH","year":"2012","unstructured":"Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: Adding value to clinical staging. J Nucl Med. 2012, 53:709-15. 10.2967\/jnumed.111.099531","journal-title":"J Nucl Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000002193","article-title":"Prognostic value of FDG-PET\/CT metabolic parameters in metastatic radioiodine-refractory differentiated thyroid cancer","volume":"43","author":"Manohar PM","year":"2018","unstructured":"Manohar PM, Beesley LJ, Bellile EL, Worden FP, Avram AM. Prognostic value of FDG-PET\/CT metabolic parameters in metastatic radioiodine-refractory differentiated thyroid cancer. Clin Nucl Med. 2018, 43:641-7. 10.1097\/RLU.0000000000002193","journal-title":"Clin Nucl Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1159\/000502229","article-title":"2019 European Thyroid Association Guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer","volume":"8","author":"Fugazzola L","year":"2019","unstructured":"Fugazzola L, Elisei R, Fuhrer D, Jarzab B, Leboulleux S, Newbold K, Smit J. 2019 European Thyroid Association Guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. Eur Thyroid J. 2019, 8:227-45. 10.1159\/000502229","journal-title":"Eur Thyroid J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy","volume":"91","author":"Durante C","year":"2006","unstructured":"Durante C, Haddy N, Baudin E, et al.. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006, 91:2892-9. 10.1210\/jc.2005-2838","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(13)70215-8","article-title":"Definition and management of radioactive iodine-refractory differentiated thyroid cancer","volume":"2","author":"Schlumberger M","year":"2014","unstructured":"Schlumberger M, Brose M, Elisei R, et al.. Definition and management of radioactive iodine-refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2014, 2:356-8. 10.1016\/S2213-8587(13)70215-8","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12149-015-0994-2","article-title":"High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma","volume":"29","author":"Kim BH","year":"2015","unstructured":"Kim BH, Kim SJ, Kim K, et al.. High metabolic tumor volume and total lesion glycolysis are associated with lateral lymph node metastasis in patients with incidentally detected thyroid carcinoma. Ann Nucl Med. 2015, 29:721-9. 10.1007\/s12149-015-0994-2","journal-title":"Ann Nucl Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000000780","article-title":"Prognostic value of (18)F-FDG PET\/CT metabolic parameters in metastatic differentiated thyroid cancers","volume":"40","author":"Masson-Deshayes S","year":"2015","unstructured":"Masson-Deshayes S, Schvartz C, Dalban C, et al.. Prognostic value of (18)F-FDG PET\/CT metabolic parameters in metastatic differentiated thyroid cancers. Clin Nucl Med. 2015, 40:469-75. 10.1097\/RLU.0000000000000780","journal-title":"Clin Nucl Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-022-00917-8","article-title":"Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: A retrospective study","volume":"12","author":"Liu Y","year":"2022","unstructured":"Liu Y, Wang Y, Zhang W. Scoring system and a simple nomogram for predicting radioiodine refractory differentiated thyroid cancer: A retrospective study. EJNMMI Res. 2022, 12:45. 10.1186\/s13550-022-00917-8","journal-title":"EJNMMI Res"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics12102381","article-title":"Using 18F-FDG-PET\/CT metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers","volume":"12","author":"Roy M","year":"2022","unstructured":"Roy M, Edet-Sanson A, Lefebvre H, Vera P, Decazes P. Using 18F-FDG-PET\/CT metrics to Predict Survival in Ra-Dio-Iodine Refractory Thyroid Cancers. Diagnostics. 2022, 12:2381. 10.3390\/diagnostics12102381","journal-title":"Diagnostics"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0107","article-title":"Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas","volume":"21","author":"Wassermann J","year":"2016","unstructured":"Wassermann J, Bernier MO, Spano JP, et al.. Outcomes and prognostic factors in radioiodine refractory differentiated thyroid carcinomas. Oncologist. 2016, 21:50-8. 10.1634\/theoncologist.2015-0107","journal-title":"Oncologist"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2010.0355","article-title":"Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy","volume":"21","author":"Miyauchi A","year":"2011","unstructured":"Miyauchi A, Kudo T, Miya A, et al.. Prognostic impact of serum thyroglobulin doubling-time under thyrotropin suppression in patients with papillary thyroid carcinoma who underwent total thyroidectomy. Thyroid. 2011, 21:707-16. 10.1089\/thy.2010.0355","journal-title":"Thyroid"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/357058-the-role-of-metabolic-parameters-of-18f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-18f-fdg-pet-ct-imaging-in-predicting-progression-free-survival-of-radioiodine-refractory-differentiated-thyroid-cancer-a-single-center-stud","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T23:53:04Z","timestamp":1748476384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/357058-the-role-of-metabolic-parameters-of-18f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-18f-fdg-pet-ct-imaging-in-predicting-progression-free-survival-of-radioiodine-refractory-differentiated-thyroid-cancer-a-single-center-stud"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.84998","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,28]]}}}